GSK Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Apr 17, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Apr 17, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, stock-repurchase
TL;DR
GSK is buying back its own stock, signaling confidence.
AI Summary
GSK plc announced on April 17, 2025, that it purchased a number of its own ordinary shares through its corporate stockbroker, Citigroup Global Markets Limited. The filing does not specify the exact number of shares or the total dollar amount of the transaction.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine report of share repurchases and does not indicate any new or significant risks.
Key Players & Entities
- GSK plc (company) — Registrant
- Citigroup Global Markets Limited (company) — Corporate stockbroker
- April 2025 (date) — Reporting period
- April 17, 2025 (date) — Date of announcement
FAQ
What was the total number of GSK ordinary shares purchased?
The filing states that a number of ordinary shares were purchased, but the specific quantity is not provided in this document.
What was the total dollar amount spent on the share repurchase?
The filing does not disclose the total dollar amount of the share repurchase.
Through which entity did GSK conduct these share repurchases?
GSK acted through its corporate stockbroker, Citigroup Global Markets Limited.
What is the par value of GSK's ordinary shares?
The ordinary shares have a par value of 31¼ pence each.
What is the purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, specifically reporting a transaction in its own shares.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 17, 2025 regarding GSK plc (GLAXF).